Who are norUrsodeoxycholic acid's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Oral chenodeoxycholic acid stimulation, Ursodeoxycholic acid, BDD with UDCA, Cholic Acids, Ursodeoxycholic Acid Capsules, Placebo Combined With Ursodeoxycholic Acid.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/norursodeoxycholic-acid.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-21 · How we verify

norUrsodeoxycholic acid — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

norUrsodeoxycholic acid (norUrsodeoxycholic acid) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: FXR agonist. Area: Liver disease.

phase 3 FXR agonist FXR Liver disease Small molecule Live · refreshed every 30 min

Target snapshot

norUrsodeoxycholic acid (norUrsodeoxycholic acid) — Dr. Falk Pharma GmbH. NorUrsodeoxycholic acid is a bile acid that acts as an FXR agonist.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
norUrsodeoxycholic acid TARGET	norUrsodeoxycholic acid	Dr. Falk Pharma GmbH	phase 3	FXR agonist	FXR
Oral chenodeoxycholic acid stimulation	Oral chenodeoxycholic acid stimulation	Lars Kristian Munck	marketed	Bile acid receptor agonist	FXR (farnesoid X receptor), TGR5
Ursodeoxycholic acid	Ursodeoxycholic acid	University of Oxford	marketed	Bile acid	Farnesoid X receptor (FXR), TGR5 receptor
BDD with UDCA	BDD with UDCA	Ewha Womans University Mokdong Hospital	phase 3	Bile acid derivative combination	FXR (farnesoid X receptor) / TGR5 (likely)
Cholic Acids	Cholic Acids	Mirum Pharmaceuticals, Inc.	phase 3	Bile acid replacement therapy	Farnesoid X receptor (FXR) and TGR5 signaling pathways
Ursodeoxycholic Acid Capsules	Ursodeoxycholic Acid Capsules	Beijing Friendship Hospital	phase 3	Bile acid	Farnesoid X receptor (FXR), TGR5 receptor
Placebo Combined With Ursodeoxycholic Acid	Placebo Combined With Ursodeoxycholic Acid	Xijing Hospital of Digestive Diseases	phase 3	Bile acid	Farnesoid X receptor (FXR), TGR5

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (FXR agonist class)

Dr. Falk Pharma GmbH · 1 drug in this class
Gannex Pharma Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). norUrsodeoxycholic acid — Competitive Intelligence Brief. https://druglandscape.com/ci/norursodeoxycholic-acid. Accessed 2026-05-21.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab